Citations (37)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Joshua Jacobs & Teresa Neeno. (2021) The importance of recognizing and managing a rare form of angioedema: hereditary angioedema due to C1-inhibitor deficiency. Postgraduate Medicine 133:6, pages 639-650.
Read now
Read now
Hilary Longhurst & Henriette Farkas. (2020) Biological therapy in hereditary angioedema: transformation of a rare disease. Expert Opinion on Biological Therapy 20:5, pages 493-501.
Read now
Read now
Articles from other publishers (35)
Michela Meregaglia, Elena Nicod & Michael Drummond. (2022) The estimation of health state utility values in rare diseases: do the approaches in submissions for NICE technology appraisals reflect the existing literature? A scoping review. The European Journal of Health Economics 24:7, pages 1151-1216.
Crossref
Crossref
Lauré M. Fijen, Philip C.G. Klein, Danny M. Cohn & Tim A. Kanters. (2023) The Disease Burden and Societal Costs of Hereditary Angioedema. The Journal of Allergy and Clinical Immunology: In Practice.
Crossref
Crossref
Jens Greve, Tamar Kinaciyan, Marcus Maurer, Barbara Dillenburger, Andreas Recke & Clemens Schöffl. (2022) Expertenkonsensus zur Prophylaxebehandlung des hereditären Angioödems. Allergo Journal 31:7, pages 22-34.
Crossref
Crossref
Jens Greve, Tamar Kinaciyan, Marcus Maurer, Barbara Dillenburger, Andreas Recke & Clemens Schöffl. (2022) Expert consensus on prophylactic treatment of hereditary angioedema. Allergo Journal International 31:7, pages 233-242.
Crossref
Crossref
Paula Busse & Allen Kaplan. (2022) Specific Targeting of Plasma Kallikrein for Treatment of Hereditary Angioedema: A Revolutionary Decade. The Journal of Allergy and Clinical Immunology: In Practice 10:3, pages 716-722.
Crossref
Crossref
Siu Hing Lo, Andrew Lloyd, Shuayb Elkhalifa, Zlatko Sisic & Floortje E. van Nooten. (2021) Time Trade-Off Utilities for Hereditary Angioedema Health and Caregiver States. PharmacoEconomics - Open 6:2, pages 231-239.
Crossref
Crossref
Konrad Bork, John T. Anderson, Teresa Caballero, Timothy Craig, Douglas T. Johnston, H. Henry Li, Hilary J. Longhurst, Cristine Radojicic & Marc A. Riedl. (2021) Assessment and management of disease burden and quality of life in patients with hereditary angioedema: a consensus report. Allergy, Asthma & Clinical Immunology 17:1.
Crossref
Crossref
William R. Lumry, Bruce Zuraw, Marco Cicardi, Timothy Craig, John Anderson, Aleena Banerji, Jonathan A. Bernstein, Teresa Caballero, Henriette Farkas, Richard G. Gower, Paul K. Keith, Donald S. Levy, H. Henry Li, Markus Magerl, Michael Manning, Marc A. Riedl, John-Philip Lawo, Subhransu Prusty, Thomas Machnig & Hilary Longhurst. (2021) Long-term health-related quality of life in patients treated with subcutaneous C1-inhibitor replacement therapy for the prevention of hereditary angioedema attacks: findings from the COMPACT open-label extension study. Orphanet Journal of Rare Diseases 16:1.
Crossref
Crossref
Joseph B. West, Kimberly Poarch & William R. Lumry. (2021) Preventive Treatment of Hereditary Angioedema: A Review of Phase III Clinical Trial Data for Subcutaneous C1 Inhibitor and Relevance for Patient Management. Clinical Therapeutics 43:12, pages 2154-2166.e1.
Crossref
Crossref
Henriette Farkas, Marcin Stobiecki, Jonny Peter, Tamar Kinaciyan, Marcus Maurer, Emel Aygören‐Pürsün, Sorena Kiani‐Alikhan, Adrian Wu, Avner Reshef, Anette Bygum, Olivier Fain, David Hagin, Aarnoud Huissoon, Miloš Jeseňák, Karen Lindsay, Vesna Grivcheva Panovska, Urs C. Steiner, Celia Zubrinich, Jessica M. Best, Melanie Cornpropst, Daniel Dix, Sylvia M. Dobo, Heather A. Iocca, Bhavisha Desai, Sharon C. Murray, Eniko Nagy & William P. Sheridan. (2021) Long‐term safety and effectiveness of berotralstat for hereditary angioedema: The open‐label APeX‐S study. Clinical and Translational Allergy 11:4.
Crossref
Crossref
Cristine RadojicicMarc A. RiedlTimothy J. CraigJessica M. BestJinky RosselliRebecca Hahn & Aleena Banerji. (2021) Patient perspectives on the treatment burden of injectable medication for hereditary angioedema. Allergy and Asthma Proceedings 42:3, pages S4-S10.
Crossref
Crossref
Aleena Banerji, Marc A. Riedl, Timothy J. Craig & Cristine Radojicic. (2021) Insights into the treatment burden of hereditary angioedema in the evolving treatment landscape. Allergy and Asthma Proceedings 42:3, pages S1-S3.
Crossref
Crossref
William R. Lumry, Karsten Weller, Markus Magerl, Aleena Banerji, Hilary J. Longhurst, Marc A. Riedl, Hannah B. Lewis, Peng Lu, Giovanna Devercelli, Gagan Jain, Marcus Maurer, J Hébert, B Ritchie, G Sussman, WH Yang, I Martinez‐Saguer, P Staubach, M Cicardi, M Shennak, RH Zaragoza‐Urdaz, J Anderson, AP Baptist, JA Bernstein, PB Boggs, PJ Busse, T Craig, M Davis‐Lorton, S Gierer, RG Gower, D Harris, DI Hong, J Jacobs, DT Johnston, HH Li, RF Lockey, P Lugar, ME Manning, DL McNeil, I Melamed, T Mostofi, T Nickel, WR Otto, AA Petrov, C Radojicic, SM Rehman, LB Schwartz, R Shapiro, E Sher, AM Smith, D Soteres, R Tachdjian, HJ Wedner, ME Weinstein & H Zafra. (2020) Impact of lanadelumab on health‐related quality of life in patients with hereditary angioedema in the HELP study. Allergy 76:4, pages 1188-1198.
Crossref
Crossref
Ana Rita Sequeira, Emmanouil Mentzakis, Olga Archangelidi & Francesco Paolucci. (2021) The economic and health impact of rare diseases: A meta-analysis. Health Policy and Technology 10:1, pages 32-44.
Crossref
Crossref
Michela Meregaglia, Amanda Whittal, Elena Nicod & Michael Drummond. (2020) ‘Mapping’ Health State Utility Values from Non-preference-Based Measures: A Systematic Literature Review in Rare Diseases. PharmacoEconomics 38:6, pages 557-574.
Crossref
Crossref
William Lumry, Teri Templeton, Laurel Omert & Donald Levy. (2020) Advances in Hereditary Angioedema: The Prevention of Angioedema Attacks With Subcutaneous C1-Inhibitor Replacement Therapy. Journal of Infusion Nursing 43:3, pages 134-145.
Crossref
Crossref
Anna Trier Heiberg Brix, Trine Mehlbye Svensson, Malin Sandberg & Anette Bygum. (2020) Hereditary angioedema: the challenges of cross-border family investigation and treatment. BMJ Case Reports 13:4, pages e231906.
Crossref
Crossref
Emel Aygören-Pürsün & Konrad Bork. (2019) Hereditäres AngioödemHereditary angioedema. hautnah 19:1, pages 30-37.
Crossref
Crossref
Emel Aygören-Pürsün & Konrad Bork. (2019) Hereditäres AngioödemHereditary angioedema. Pädiatrie & Pädologie 55:1, pages 12-20.
Crossref
Crossref
Stephen Betschel, Jacquie Badiou, Karen Binkley, Rozita Borici-Mazi, Jacques Hébert, Amin Kanani, Paul Keith, Gina Lacuesta, Susan Waserman, Bill Yang, Emel Aygören-Pürsün, Jonathan Bernstein, Konrad Bork, Teresa Caballero, Marco Cicardi, Timothy Craig, Henriette Farkas, Anete Grumach, Connie Katelaris, Hilary Longhurst, Marc Riedl, Bruce Zuraw, Magdelena Berger, Jean-Nicolas Boursiquot, Henrik Boysen, Anthony Castaldo, Hugo Chapdelaine, Lori Connors, Lisa Fu, Dawn Goodyear, Alison Haynes, Palinder Kamra, Harold Kim, Kelly Lang-Robertson, Eric Leith, Christine McCusker, Bill Moote, Andrew O’Keefe, Ibraheem Othman, Man-Chiu Poon, Bruce Ritchie, Charles St-Pierre, Donald Stark & Ellie Tsai. (2019) The International/Canadian Hereditary Angioedema Guideline. Allergy, Asthma & Clinical Immunology 15:1.
Crossref
Crossref
Emel Aygören-Pürsün & Konrad Bork. (2019) Neue Mittel in der Pipeline. Der Deutsche Dermatologe 67:11, pages 872-881.
Crossref
Crossref
Emel Aygören-Pürsün & Konrad Bork. (2019) Hereditäres AngioödemHereditary angioedema. Der Internist 60:9, pages 987-995.
Crossref
Crossref
Emel Aygören‐Pürsün, Daniel F. Soteres, Sandra A. Nieto‐Martinez, Jim Christensen, Kraig W. Jacobson, Dumitru Moldovan, Arthur Van Leerberghe, Yongqiang Tang, Peng Lu, Moshe Vardi, Jennifer Schranz & Inmaculada Martinez‐Saguer. (2019) A randomized trial of human C1 inhibitor prophylaxis in children with hereditary angioedema. Pediatric Allergy and Immunology 30:5, pages 553-561.
Crossref
Crossref
Anette Bygum. (2019) Hereditary Angio-Oedema for Dermatologists. Dermatology 235:4, pages 263-275.
Crossref
Crossref
Marc A Riedl, Aleena Banerji, Michael E Manning, Earl Burrell, Namita Joshi, Dipen Patel, Thomas Machnig, Ming-Hui Tai & Douglas J Watson. (2018) Treatment patterns and healthcare resource utilization among patients with hereditary angioedema in the United States. Orphanet Journal of Rare Diseases 13:1.
Crossref
Crossref
Rosanna Spanò, Nadia Di Paola, Maria Bova & Alessandro Barbarino. (2018) Value co-creation in healthcare: evidence from innovative therapeutic alternatives for hereditary angioedema. BMC Health Services Research 18:1.
Crossref
Crossref
Lisa Fu, Amin Kanani, Gina Lacuesta, Susan Waserman & Stephen Betschel. (2018) Canadian physician survey on the medical management of hereditary angioedema. Annals of Allergy, Asthma & Immunology 121:5, pages 598-603.
Crossref
Crossref
M. A. Riedl, E. Aygören-Pürsün, J. Baker, H. Farkas, J. Anderson, J. A. Bernstein, L. Bouillet, P. Busse, M. Manning, M. Magerl, M. Gompels, A. P. Huissoon, H. Longhurst, W. Lumry, B. Ritchie, R. Shapiro, D. Soteres, A. Banerji, M. Cancian, D. T. Johnston, T. J. Craig, D. Launay, H. H. Li, M. Liebhaber, T. Nickel, J. Offenberger, W. Rae, R. Schrijvers, M. Triggiani, H. J. Wedner, S. Dobo, M. Cornpropst, D. Clemons, L. Fang, P. Collis, W. P. Sheridan & M. Maurer. (2018) Evaluation of avoralstat, an oral kallikrein inhibitor, in a Phase 3 hereditary angioedema prophylaxis trial: The OPuS-2 study. Allergy 73:9, pages 1871-1880.
Crossref
Crossref
William R. Lumry, Timothy Craig, Bruce Zuraw, Hilary Longhurst, James Baker, H. Henry Li, Jonathan A. Bernstein, John Anderson, Marc A. Riedl, Michael E. Manning, Paul K. Keith, Donald S. Levy, Teresa Caballero, Aleena Banerji, Richard G. Gower, Henriette Farkas, John-Philip Lawo, Ingo Pragst, Thomas Machnig & Douglas J. Watson. (2018) Health-Related Quality of Life with Subcutaneous C1-Inhibitor for Prevention of Attacks of Hereditary Angioedema. The Journal of Allergy and Clinical Immunology: In Practice 6:5, pages 1733-1741.e3.
Crossref
Crossref
Anette Bygum, Paula Busse, Teresa Caballero & Marcus Maurer. (2017) Disease Severity, Activity, Impact, and Control and How to Assess Them in Patients with Hereditary Angioedema. Frontiers in Medicine 4.
Crossref
Crossref
Marcus Tolentino Silva, Monica Caicedo Roa & Tais Freire Galvao. (2017) Health-related quality of life in the Brazilian Amazon: a population-based cross-sectional study. Health and Quality of Life Outcomes 15:1.
Crossref
Crossref
Aharon Kessel, Henriette Farkas, Shmuel Kivity, Nóra Veszeli, Kinga V. Kőhalmi & Batya Engel-Yeger. (2017) The relationship between anxiety and quality of life in children with hereditary angioedema. Pediatric Allergy and Immunology 28:7, pages 692-698.
Crossref
Crossref
Dorottya Csuka, Nóra Veszeli, Lilian Varga, Zoltán Prohászka & Henriette Farkas. (2017) The role of the complement system in hereditary angioedema. Molecular Immunology 89, pages 59-68.
Crossref
Crossref
Teresa Caballero & Nieves Prior. (2017) Burden of Illness and Quality-of-Life Measures in Angioedema Conditions. Immunology and Allergy Clinics of North America 37:3, pages 597-616.
Crossref
Crossref
Marc A. Riedl, Aleena Banerji, Paula J. Busse, Douglas T. Johnston, Mark A. Davis-Lorton, Shital Patel, Howard Parr, Joseph Chiao, Douglas J. Watson, Earl Burrell & Thomas Machnig. (2017) Patient satisfaction and experience with intravenously administered C1-inhibitor concentrates in the United States. Annals of Allergy, Asthma & Immunology 119:1, pages 59-64.
Crossref
Crossref